Navigation Links
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
Date:12/16/2008

cts for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                            Robert Flamm, Ph.D.
    Russo Partners LLC                   Russo Partners LLC
    Tel: (619) 814-3510                  Tel: (212) 845-4226
    Fax: (619) 955-5318                  Email:
    Email:                               robert.flamm@russopartnersllc.com
    ian.stone@russopartnersllc.com       www.russopartnersllc.com

This News Release contains certain forward-looking statements and information regarding Helix's drug development plans, which statements and information can be identified by the use of forward-looking terminology such as "intends", "plans", "expects", "pending", "to occur", "objective", "believes", "on track", "is being designed", "proceeding", "intention", "to seek", "projects", "anticipates", "2009", "2010", "2012", "assuming", "continuing", "with a view to", "if", "developing", or variations thereon, or that events "could" or "would" occur or be achieved, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future, are not historical facts, and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: Helix's need for further financing, which may not be available; uncertainty whether the Company's products under development, includin
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
2. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
3. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
4. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
5. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
7. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
8. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
9. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
10. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
11. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... says more than 2 dozen contain dangerous ingredients not ... -- The U.S. Food and Drug Administration warned consumers ... for weight loss because they contain undeclared ingredients that ... sold in some retail stores and on the Internet ...
... developed a new generation of microscopic particles for ... nanoparticle platforms that may be readily adapted for ... , According to the investigators at Memorial ... particles are biologically safe, stable, and small enough ...
... UPTON, NY Scientists at the U.S. Department of ... structure of a third subtype of botulinum neurotoxin ... the disease botulism, and is also used in cosmetic ... a hyperactive bladder. The detailed structure, published online December ...
... you,ve been offered the perfect job. The not-so-good news ... the disabled, people with diseases like HIV, or those who ... room, undergoing a medical exam to qualify for a job ... Aviv University brings excellent news. , Medical exams are often ...
... are less sensitive to thermal (hot and cold) sensations later ... London). The study, published in the journal Pain , ... in early development may alter how children respond to painful ... 43 eleven-year-old children born at less than 26 weeks of ...
... switch ,on, in those with lupus, rheumatoid arthritis , , ... potential autoimmune disease-causing cells, but these cells stay in ... cells that attack the body cause autoimmune diseases such ... cells in healthy adults are true precursors of the ...
Cached Medicine News:Health News:FDA Warns About Weight Loss Products 2Health News:FDA Warns About Weight Loss Products 3Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 2Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 3Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:A simple questionnaire to replace a doctor's exam 2Health News:Premature babies have altered sensory responses in later life 2
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... Medical Simulation Corporation (MSC) proudly announces a new agreement ... Medical School and a healthcare leader in patient quality, ... system, Simantha ®, and MSC,s curriculum and training ... and patient safety goals over the next three years. ...
... Pfizer (NYSE: PFE ) today ... Inc., a privately held drug discovery and clinical development ... a wholly owned subsidiary of Pfizer Inc.   ... Pfizer Inc: Working together for a healthier ...
Cached Medicine Technology:Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital 2
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
... Double Antibody Estradiol,is an 125I ... use in the quantitative,measurement of ... of precocious puberty in girls,and ... the,differential diagnosis of amenorrhea. It ...
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... most potent, naturally secreted estrogen and is ... [1]. In the ovary, estradiol is produced ... less potent estrogen derived from androstenedione. Estrone ... tissues. In men, small amounts of estradiol ...
Medicine Products: